SIWA-318

N/A

Report date: 2024/11/06 10:38:21

Base Information

Drug NameSIWA-318
Drug Alias NameSIWA-318HSIWA-318318H
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAdvanced glycosylation end product-specific receptor antagonists
TargetsAdvanced glycosylation end product-specific receptor
Therapy Area/IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Muscular Dystrophies +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSiwa Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSiwa Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Muscular Dystrophies +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A